Plaquenil and Retinal Complications: Highlights and Recommendations

Plaquenil (hydroxychloroquine) is a medication used to treat certain autoimmune diseases. Retinal complications have been associated with long-term use of Plaquenil treatment. However, these complications usually occur after a year or more of continuous use.

As eye doctors, it is important to regularly check the eyes of patients taking Plaquenil. However, eye examinations are usually not needed before 6 months because the risk of retinal complications is almost non-existent during this time.

Retinal complications rarely occur in patients taking Plaquenil, usually over one year. However, the risk of retinal complications is related to the total dose taken. In particular, Plaquenil intake above 100,000 mg may increase the risk of retinal complications.

Prophylactic (protective) doses, usually recommended at 200 or 400 mg, are known to be effective in preventing lung infections. These low doses are generally free from the risk of retinal complications.

However, widespread use of Plaquenil in the general population may rarely result in the emergence of unknown personal sensitivities. It may therefore be advantageous for individuals in risk groups to use this medicine.

In conclusion, Plaquenil use requires caution in terms of retinal complications, but low doses are generally safe. Regular eye checks by the ophthalmologist and proper use of the drug by the patient play an important role in minimizing potential risks.